Table 4.

Following vaccination, the MCP-low patients (serum MCP-1 level <250 pg/mL) can be further characterized into the response-low (<50% increase in serum MCP-1 levels postvaccination) and response-high (>50% increase in serum MCP-1 levels postvaccination)

Study no.Serum MCP-1
MCP-1% ↑AgeRaceGradeStage 2or aboveTumor T2or aboveNode-positiveNo.nodeEstrogen/progesterone receptor +/+HER-2/neuoncogene 3+ by IHCChemotherapy
PrePost
Response-low
    B5440.835.9−1245WhitePoorYesYesYes4YesYesYes
    B53135130.9−350WhiteModYesNoYes2NoNoYes
    NNV5230.16255.441159OtherModNoNoNo0NoYesYes
    NNV485.998.51553WhiteModNoNoNo0YesNoYes
    B51237.6277.61773WhiteWellYesNoYes1YesNoNo
    NNV1528.836.72758WhiteNoNoNo0YesNoNo
    NNV10196.7251.62857WhiteWellNoNoNo0YesNo
    NNV2259.3779.63453WhiteNoNoNo0No
    NNV20157.18212.123555WhiteModNoNoNo0YesNoNo
    B5697.27131.383543WhitePoorYesNoYes6NoYesYes
    NNV1150.1970.234045OtherPoorNoNoNo0NoNoYes
    NNV1986.4122.164150OtherModNoNoNo0YesNoYes
    B4670.71024452WhiteModYesNoYes2NoYesYes
    NNV14123.33182.14874WhiteModNoNoNo0YesNo
    B4193138.64949WhiteWellYesNoYes2YesNoYes
Response-high
    B44155.32239.445462OtherPoorYesYesYes3NoNoYes
    B55244.6381.55648WhitePoorYesYesYes8YesYesYes
    NNV13178.08319.047952WhitePoorYesYesNo0YesYesYes
    B5747.8898662WhitePoorYesNoYes1NoYesYes
    B50136.33257.68951WhitePoorYesYesYes5NoNoYes
    NNV2362.7130.0810746WhitePoorYesYesNo0YesNoYes
    NNV680.35208.716046WhiteModNoNoNo0YesNoYes
  • NOTE: Response-high patients show worse clinical prognostic variables. NNV, node-negative patients; B, node-positive breast cancer patients; Poor, poorly differentiated (grade 3); Mod, moderately differentiated (grade 2); Well, well-differentiated (grade 1); IHC, immunohistochemistry.